Visual guide links IHC, morphology, prognosis
A posted molecular classification chart visually ties breast‑cancer morphology and IHC patterns to prognosis—from luminal to triple‑negative/claudin‑low—useful for cytologists integrating molecular context into interpretations. Quick visual mapping can streamline communication with clinicians about likely molecular subtypes. (x.com)
The posted visual uses ER, PR, HER2 and Ki‑67 as the IHC surrogates that map into intrinsic groups labeled luminal A, luminal B, HER2‑enriched and basal‑like/triple‑negative on contemporary clinicopathologic charts. (pathologyoutlines.com)) Claudin‑low is shown as a separate aggressive phenotype largely nested within triple‑negative cases and characterized by low CLDN3/4/7 and E‑cadherin, high EMT and stemness signatures, and worse overall survival in cohort analyses (~10–12% of profiled tumors in large datasets). (link.springer.com)) The chart’s prognostic axis reflects recent guideline-driven emphasis on HER2 reporting: the 2023 ASCO‑CAP/CAP updates formalized HER2‑low (IHC 1+ or 2+/ISH‑) categories that alter treatment eligibility and reporting practice. (cap.org)) Cytology‑specific validation is flagged on similar resources: ER/PR/HER2 testing on formalin‑fixed cell blocks is acceptable when laboratory validation and preanalytic controls are documented, but multicenter comparative series between cell blocks and matched histology remain limited. (acsjournals.onlinelibrary.wiley.com)) Epidemiologic context embedded in these maps shows luminal A at roughly 30–40% of cases, luminal B 20–30%, HER2‑enriched 12–20% and triple‑negative about 15–20%, numbers commonly cited when translating an IHC pattern into expected prognosis. (pathologyoutlines.com)) Operationally, the visual guide can be used to build reflex algorithms in cytology workflows—e.g., triple‑negative morphology plus negative ER/PR/HER2 on cell block prompting NGS or gene‑expression profiling in academic centers because TNBC is molecularly heterogeneous and often requires advanced molecular triage for trial or therapy matching. (aacrjournals.org))
